Increased levels of citrullinated antithrombin in plasma of patients with rheumatoid arthritis and colorectal adenocarcinoma determined by a newly developed ELISA using a specific monoclonal antibody

Thrombosis and Haemostasis

Volumn 104, Issue 6, 2010, Pages 1143-1149

  Ordóñez, Adriana ^a   Yélamos, Jose ^b   Pedersen, Shona ^c   Miñano, Antonia ^a   Conesa Zamora, Pablo ^d   Kristensen, Soren R ^c   Stender, Mogens T ^c   Thorlacius Ussing, Ole ^c   Martínez Martínez, Irene ^a   Vicente, Vicente ^a   Corral, Javier ^a  

^a UNIVERSITY OF MURCIA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d Hospital Universitario Santa Maria del Rosell   (Spain)

Author keywords

Antithrombin; Cancer; Citrullination; Monoclonal antibody; Rheumatoid arthritis

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; CITRULLINATED ANTITHROMBIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; VEIN THROMBOSIS;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTITHROMBINS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOOD COAGULATION; CITRULLINE; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR XA; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL; UP-REGULATION; VENOUS THROMBOSIS;

EID: 78649719869     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-05-0297     Document Type: Article

References (42)

1. Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J 2000; 19: 1176-1179.
2. Wells L, et al. Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science 2001; 291: 2376-2378.
3. Akimoto Y, et al. Elevation of the post-translational modification of proteins by O-linked N-acetylglucosamine leads to deterioration of the glucose-stimulated insulin secretion in the pancreas of diabetic Goto-Kakizaki rats. Glycobiology 2007; 17: 127-140.
4. Kim JK, et al. Multiple sclerosis: an important role for post-translational modifications of myelin basic protein in pathogenesis. Mol Cell Proteomics 2003; 2: 453-462.
5. Ishida-Yamamoto A, et al. Decreased deiminated keratin K1 in psoriatic hyperproliferative epidermis. J Invest Dermatol 2000; 114: 701-705.
6. Moscarello MA, et al. The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochem Res 2007; 32: 251-256.
7. Nijenhuis S, et al. Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin Chim Acta 2004; 350: 17-34.
8. Suzuki A, et al. Citrullination by peptidylarginine deiminase in rheumatoid arthritis. Ann NY Acad Sci 2007; 1108: 323-339.
9. Vossenaar ER, et al. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 2003; 25: 1106-1118.
10. van Venrooij WJ, Pruijn GJ. Citrullination: A small change for a protein with great consequences for rheumatoid arthritis. Arthritis Res 2000; 2: 249-251.
11. Tarcsa E, et al. Protein unfolding by peptidylarginine deiminase. Substrate specificity and structural relationships of the natural substrates trichohyalin and filaggrin. J Biol Chem 1996; 271: 30709-30716.
12. Gyorgy B, et al. Citrullination: a posttranslational modification in health and disease. Int J Biochem Cell Bio 2006; 38: 1662-1677.
13. Asaga H, et al. Selective deimination of vimentin in calcium ionophore-induced apoptosis of mouse peritoneal macrophages. Biochem Biophys Res Commun 1998; 243: 641-646.
14. Jang B, et al. Involvement of peptidylarginine deiminase-mediated post-translational citrullination in pathogenesis of sporadic Creutzfeldt-Jakob disease. Acta Neuropathol 2010; 119: 199-210.
15. Tanikawa C, et al. Regulation of protein Citrullination through p53/PADI4 network in DNA damage response. Cancer Res 2009; 69: 8761-8769.
16. Loos T, et al. Citrullination of CXCL10 and CXCL11 by peptidylarginine deiminase: a naturally occurring posttranslational modification of chemokines and new dimension of immunoregulation. Blood 2008; 112: 2648-2656.
17. Hernández-Espinosa D, et al. Factors with conformational effects on haemostatic serpins: implications in thrombosis. Thromb Haemost 2007; 98: 557-563.
18. Chang X, et al. The inhibition of antithrombin by peptidylarginine deiminase 4 may contribute to pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 293-298.
19. Pike RN, et al. Heparin-dependent modification of the reactive center arginine of antithrombin and consequent increase in heparin binding affinity. J Biol Chem 1997; 272: 19652-19655.
20. Ordóñez A, et al. Effect of citrullination on the function and conformation of antithrombin. FEBS J 2009; 276: 6763-6772.
21. Ishiguro K, et al. Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest 2000; 106: 873-878.
22. Chang X, et al. Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer 2009; 9: 40.
23. Sud R, Khorana AA. Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model. Thromb Res 2009; 123 (Suppl): S18-21.
24. Kuderer NM, et al. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. Clin Oncol 2009; 27: 4902-4911.
25. Mameli A, et al. Rheumatoid arthritis and thrombosis. Clin Exp Rheumatol 2009; 27: 846-855.
26. Matta F, et al. Risk of venous thromboembolism with rheumatoid arthritis. Thromb Haemost 2009; 101: 134-138.
27. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497.
28. Stender MT, et al. Preoperative plasma D-dimer is a predictor of postoperative deep venous thrombosis in colorectal cancer patients: a clinical, prospective cohort study with one-year follow-up. Dis Colon Rectum 2009; 52: 446-451.
29. Wegner N, et al. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev 2010; 233: 34-54.
30. Yamada R, et al. Citrullinated proteins in rheumatoid arthritis. Front Biosci 2005; 10: 54-64.
31. Schellekens GA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43: 155-163.
32. Pruijn GJ, et al. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther 2010; 12: 203.
33. van Venrooij WJ, et al. Anti-CCP Antibody, a Marker for the Early Detection of Rheumatoid Arthritis. Ann NY Acad Sci 2008; 1143: 268-285.
34. van Gaalen FA, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004; 50: 709-715.
35. Szekanecz Z, et al. Anti-citrullinated protein antibodies in rheumatoid arthritis: as good as it gets? Clin Rev Allergy Immunol 2008; 34: 26-31.
36. Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med 2008; 121: S9-14.
37. Undas A, et al. Thrombin generation in rheumatoid arthritis: dependence on plasma factor composition. Thromb Haemost 2010; 104: 224-230.
38. Chang X, Han J. Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors. Mol Carcinog 2006; 45: 183-196.
39. Cohen AT, et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost. 2005; 94: 750-759.
40. Boccaccio C, Comoglio PMJ. Genetic link between cancer and thrombosis. Clin Oncol 2009; 27: 4827-4833.
41. Khong TL, et al. Angiogenesis as a therapeutic target in arthritis: learning the lessons of the colorectal cancer experience. Angiogenesis 2007; 10: 243-258.
42. O'Reilly MS. Antiangiogenic antithrombin. Semin Thromb Hemost 2007; 33: 660-666.